A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria - Concepedia

Concepedia

Publication | Closed Access

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

392

Citations

21

References

2011

Year

Sarbjit S. Saini, Karin Rosén, Hsin-Ju Hsieh, Dennis A. Wong, Edward Conner, Allen P. Kaplan, Sheldon L. Spector, Marcus Maurer

Journal of Allergy and Clinical Immunology

PharmacotherapyDermatologyDose-ranging StudyMedicineDrug AllergyClinical AllergyHypersensitivitySingle-dose Omalizumab

References

	Year	Citations

Page 1